

PRESS RELEASE

Cell4Cure's Innovative Immune Tolerance Platform Integral to PhD Thesis Successfully Defended by Dr. Gillian Dao Nyesiga at Malmö University

Solna, Sweden, 26 February 2025, – Cell4Cure AB, a privately held Swedish biotech company at the forefront of immune tolerance therapies, today announced that its proprietary technology platform was a key component of the PhD thesis successfully defended by Dr. Gillian Dao Nyesiga on February 21 at Malmö University

Dr. Dao Nyesiga's research included extensive work on Cell4Cure's antigen-specific dendritic cell tolerance platform, contributing valuable insights into its potential clinical applications. This research resulted in two significant contributions. The first was published in *Frontiers in Immunology* in 2023 ([link](#)), while the second is currently under review for publication.

Leadership Perspective on Scientific Contribution

Jan Holgersson, Chief Scientific Officer (CSO) of Cell4Cure, emphasized the importance of this research in advancing immune tolerance therapies:

"Dr. Gillian Dao Nyesiga's work has not only validated key aspects of our technology but has also provided critical scientific advancements that support our mission to develop transformative immune tolerance therapies."

Dr. Dao Nyesiga expressed her appreciation for the opportunity to contribute to this pioneering field:

"Being part of this research effort with Cell4Cure has been an incredibly rewarding experience. The potential of dendritic cell-based immune tolerance therapies is profound, and I am honored to have played a role in advancing this technology."

About Cell4Cure

Founded in 2023, **Cell4Cure AB**, is a Swedish biotech company pioneering immune tolerance therapies to address critical challenges such as anti-drug antibodies (ADAs), autoimmune diseases, and transplant rejections. The company's proprietary platform leverages ex vivo-generated dendritic cells (DCs) engineered to induce antigen-specific tolerance while preserving essential immune function.

Backed by \$30 million in research and development investments, Cell4Cure has achieved key milestones, including European Medicinal Agency (EMA) approval for clinical trials and the establishment of robust GMP manufacturing processes.

For more information, please contact:

Christina Herder, CEO

Telephone: +46 703747156

E-mail: christina.herder@cell4cure.com more information visit www.cell4cure.com